Transduced PEP-1-PON1 proteins regulate microglial activation and dopaminergic neuronal death in a Parkinson's disease model

Biomaterials

Volumn 64, Issue , 2015, Pages 45-56

  Kim, Mi Jin ^a   Park, Meeyoung ^a   Kim, Dae Won ^b   Shin, Min Jea ^a   Son, Ora ^a   Jo, Hyo Sang ^a   Yeo, Hyeon Ji ^a   Cho, Su Bin ^a   Park, Jung Hwan ^a   Lee, Chi Hern ^a   Kim, Duk Soo ^c   Kwon, Oh Shin ^d   Kim, Joon ^e   Han, Kyu Hyung ^a   Park, Jinseu ^a   Eum, Won Sik ^a   Choi, Soo Young ^a  

^a Hallym University   (South Korea)

^b Gangneung Wonju National University   (South Korea)

^c Soonchunhyang University College of Medicine   (South Korea)

^d Kyungpook National University   (South Korea)

^e Korea University   (South Korea)

Author keywords

Dopaminergic neuronal death; Inflammation; Oxidative stress; Parkinson's disease; PEP 1 PON1; Protein therapy

Indexed keywords

CELL DEATH; DISEASE CONTROL; LIPOPROTEINS; MAMMALS; NEURONS; OXIDATIVE STRESS; PATHOLOGY; PHOSPHOLIPIDS; PROTEINS;

1-METHYL-4-PHENYLPYRIDINIUM; INFLAMMATION; MATRIX METALLOPROTEINASE 9 (MMP 9); NEURODEGENERATIVE DISORDERS; NEURONAL DEATH; PARKINSON'S DISEASE; PEP-1-PON1; PROTEIN TRANSDUCTION DOMAINS;

NEURODEGENERATIVE DISEASES;

1 METHYL 4 PHENYLPYRIDINIUM; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; BETA ACTIN; CASPASE 3; CYCLOOXYGENASE 2; GELATINASE B; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HIGH DENSITY LIPOPROTEIN; HYBRID PROTEIN; I KAPPA B ALPHA; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; LOW DENSITY LIPOPROTEIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PEP 1 PON1 FUSION PROTEIN; PHOSPHOLIPID; PROTEIN BAX; PROTEIN BCL 2; REACTIVE OXYGEN METABOLITE; STRESS ACTIVATED PROTEIN KINASE; SYNAPTOTAGMIN I; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ARYLDIALKYLPHOSPHATASE; CELL PENETRATING PEPTIDE; MMP9 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DNA FRAGMENTATION; DOPAMINERGIC NERVE CELL; HUMAN; HUMAN CELL; INFLAMMATION; LIPID OXIDATION; MALE; MESENCEPHALON; MICROGLIA; MITOCHONDRION; MOUSE; MPTP-INDUCED PARKINSONISM; NERVE CELL NECROSIS; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; SUBSTANTIA NIGRA; ANIMAL; APOPTOSIS; BIOSYNTHESIS; BRAIN; CELL CULTURE; DRUG EFFECTS; ENZYME INDUCTION; GENE THERAPY; GENE VECTOR; GENETIC TRANSDUCTION; IMMUNOLOGY; METABOLISM; MITOCHONDRIAL MEMBRANE POTENTIAL; NEUROBLASTOMA; PARKINSONIAN DISORDERS; PATHOLOGY; PHYSIOLOGY; PROTEIN TERTIARY STRUCTURE; THERAPEUTIC USE; TUMOR CELL LINE;

MUS;

ANIMALS; APOPTOSIS; ARYLDIALKYLPHOSPHATASE; BRAIN; CELL LINE, TUMOR; CELL-PENETRATING PEPTIDES; CELLS, CULTURED; DOPAMINERGIC NEURONS; ENZYME INDUCTION; GENETIC THERAPY; GENETIC VECTORS; HUMANS; LIPOPOLYSACCHARIDES; MATRIX METALLOPROTEINASE 9; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICE; MICROGLIA; NEUROBLASTOMA; OXIDATIVE STRESS; PARKINSONIAN DISORDERS; PROTEIN STRUCTURE, TERTIARY; REACTIVE OXYGEN SPECIES; RECOMBINANT FUSION PROTEINS; TRANSDUCTION, GENETIC;

EID: 84937439736     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2015.06.015     Document Type: Article

References (50)

1. Bin Ali A., Zhang Q., Lim Y.K., Fang D., Retnam L., Lim S.K. Expression of major HDL-associated antioxidant PON-1 is gender dependent and regulated during inflammation. Free Radic. Biol. Med. 2003, 34:824-829.
2. Jaeschke H. Reactive oxygen and mechanisms of inflammatory liver injury: present concepts. J.Gastroenterol. Hepatol. 2011, 26(Suppl.1):173-179.
3. Nofer J.R., Kehrel B., Fobker M., Levkau B., Assman G., von Eckardstein A. HDL and arteriosclerosis: beyond reverse cholesterol transport. Atherosclerosis 2002, 161:1-16.
4. Sugano M., Tsuchida K., Makino N. High-density lipoproteins protect endothelial cells from tumor necrosis factor-a-induced apoptosis. Biochem. Biophys. Res. Commun. 2000, 272:872-876.
5. Watson A.D., Berliner J.A., Hama S.Y., La Du B.N., Faull K.F., Fogelman A.M., et al. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J.Clin. Invest. 1995, 96:2882-2891.
6. Gao H.M., Liu B., Zhang W., Hong J.S. Novel anti-inflammatory therapy for Parkinson's disease. Trends Pharmacol. Sci. 2003, 24:395-401.
7. Peterson L.J., Flood P.M. Oxidative stress and microglial cells in Parkinson's disease. Mediat. Inflamm. 2012, 2012:401264.
8. Goping G., Pollard H.B., Adeyemo O.M., Kuijpers G.A. Effect of MPTP on dopaminergic neurons in the goldfish brain: a light and electron microscope study. Brain Res. 1995, 687:35-52.
9. Singer T.P., Ramsay R.R. Mechanism of the neurotoxicity of MPTP: an update. FEBS Lett. 1990, 274:1-8.
10. Zheng H.F., Yang Y.P., Hu L.F., Wang M.X., Wang F., Cao L.D., et al. Autophagic impairment contributes to systemic inflammation-induced dopaminergic neuron loss in the midbrain. PLoS One 2013, 6:8.
11. Wilms H., Zecca L., Rosenstiel P., Sievers J., Deuschl G., Lucius R. Inflammation in Parkinson's diseases and other neurodegenerative diseases: cause and therapeutic implications. Curr. Pharm. Des. 2007, 13:1925-1928.
12. Precourt L.P., Amre D., Denis M.C., Lavoie J.C., Delvin E., Seidman E., et al. The three-gene paraoxonase family: physiologic roles, actions and regulation. Atherosclerosis 2011, 214:20-36.
13. Tomas M., Latorre G., Senti M., Marrugat J. The antioxidant function of high density lipoproteins: a new paradigm in atherosclerosis. Rev. Esp. Cardiol. 2004, 57:557-569.
14. Aviram M., Rosenblat M., Bisgaier C.L., Newton R.S., Primo-Parmo S.L., La Du B.N. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J.Clin. Invest. 1998, 101:1581-1590.
15. Rozenberg O., Rosenblat M., Coleman R., Shih D.M., Aviram M. Paraoxonase (PON1) deficiency is associated with increased macrophage oxidative stress: studies in PON1-knockout mice. Free Radic. Biol. Med. 2003, 34:774-784.
16. Rozenberg O., Shih D.M., Aviram M. Human serum paraoxonase1 decreases macrophage cholesterol biosynthesis: possible role for its phospholipase-A2-like activity and lysophosphatidylcholine formation. Arterioscler. Thromb. Vasc. Biol. 2003, 23:461-467.
17. Fuhrman B., Volkova N., Aviram M. Oxidative stress increases the expression of the CD36 scavenger receptor and the cellular uptake of oxidized low-density lipoprotein in macrophages from atherosclerotic mice: protective role of antioxidants and of paraoxonase. Atherosclerosis 2002, 161:307-316.
18. Morris M.C., Depollier J., Mery J., Heitz F., Divita G. Apeptide carrier for the delivery of biologically active proteins into mammalian cells. Nat. Biotechnol. 2001, 19:1173-1176.
19. Kim M.J., Jeong H.J., Kim D.W., Sohn E.J., Jo H.S., Kim D.S., et al. PEP-1-PON1 protein regulates inflammatory response in Raw 264.7 macrophages and ameliorates inflammation in a TPA-induced animal model. PLOS One 2014, 9:e86034.
20. Kwon D.J., Bae Y.S., Ju S.M., Youn G.S., Choi S.Y., Park J. Salicortin suppresses lipopolysaccharide-stimulated inflammatory responses via blockade of NF-kB and JNK activation in RAW 264.7 macrophages. BMB Rep. 2014, 47:318-323.
21. Han W., Wang L., Yin B., Peng X. Characterization of a novel posttranslational modification in polypyrimidine tract-binding proteins by SUMO1. BMB Rep. 2014, 47:233-238.
22. Kim M.J., Kim D.W., Park J.H., Kim S.J., Lee C.H., Yong J.I., et al. PEP-1-SIRT2 inhibits inflammatory response and oxidative stress-induced cell death via expression of antioxidant enzymes in murine macrophages. Free Radic. Biol. Med. 2013, 63:432-445.
23. Lee Y.P., Kim D.W., Kang H.W., Hwang J.H., Jeong H.J., Sohn E.J., et al. PEP-1-heat shock protein 27 protects from neuronal damage in cells and in a Parkinson's disease mouse model. FEBS J. 2012, 279:1929-1942.
24. Ahn E.H., Kim D.W., Shin M.J., Kim Y.N., Kim H.R., Woo S.J., et al. PEP-1-ribosomal protein S3 protects dopaminergic neurons in an MPTP-induced Parkinson's disease mouse model. Free Radic. Biol. Med. 2013, 55:36-45.
25. Youn J.K., Kim D.W., Kim S.T., Park S.Y., Yeo E.J., Choi Y.J., et al. PEP-1-HO-1 prevents MPTP-induced degeneration of dopaminergic neurons in a Parkinson's disease mouse model. BMB Rep. 2014, 47:569-574.
26. Kim D.S., Ryu H.J., Kim J.E., Kang T.C. The reverse roles of transient receptor potential canocical channel-3 and -6 in neuronal death following pilocarpine-induced status epilepticus. Cell. Mol. Neurobiol. 2013, 33:99-109.
27. B receptor associates with regulators of G-protein signaling 4 protein in the mouse prefrontal cortex and hypothalamus. BMB Rep. 2014, 47:324-329.
28. Whitton P.S. Inflammation as a causative factor in the aetiology of Parkinson's disease. Br. J. Pharmacol. 2007, 150:963-976.
29. Uto T., Suangkaew N., Morinaga O., Kariyazono H., Oiso S., Shoyama Y. Eriobotryae folium extract suppresses LPS-induced iNOS and COX-2 expression by inhibition of NF-kappaB and MAPK activation in murine macrophages. Am. J. Chin. Med. 2010, 38:985-994.
30. Vali S., Mythri R.B., Jagatha B., Padiadpu J., Ramanujan K.S., Andersen J.K., et al. Integrating glutathione metabolism and mitochondrial dysfunction with implications for Parkinson's disease: a dynamic model. Neuroscience 2007, 149:917-930.
31. Bertram J., Peacock J.W., Tan C., Mui A.L., Chung S.W., Gleave M.E., et al. Inhibition of the phosphatidylinositol 3'-kinase pathway promotes autocrine Fas-induced death of phosphatase and tensin homologue-deficient prostate cancer cells. Cancer Res. 2006, 66:4781-4788.
32. +- or 6-OHDA-treated human neuroblastoma SK-N-BE(2)C cells. Neurochem. Int. 2010, 56:437-442.
33. Lorenzl S., Calingasan N., Yang L., Albers D.S., Shugama S., Gregorio J., et al. Matrix metalloproteinase-9 is elevated in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice. Neuromol. Med. 2004, 5:119-132.
34. Loh K.P., Huang S.H., De Silva R., Tan B.K., Zhu Y.Z. Oxidative stress: apoptosis in neuronal injury. Curr. Alzheimer Res. 2006, 3:327-337.
35. Steinberg D. At last, direct evidence that lipoxygenases play a role in atherogenesis. J.Clin. Invest. 1999, 103:1487-1488.
36. Hamilton J.A., Byrne R., Jessup W., Kanagasundaram V., Whitty G. Comparison of macrophage responses to oxidized low-density lipoprotein and macrophage colony-stimulating factor (M-CSF or CSF-1). Biochem. J. 2001, 354:179-187.
37. Costa L.G., Vitalone A., Cole T.B., Furlong C.E. Modulation of paraoxonase (PON1) activity. Biochem. Pharmacol. 2005, 69:541-550.
38. Ferretti G., Bacchetti T., Moroni C., Savino S., Liuzzi A., Balzola F., et al. Paraoxonase activity in high-density lipoproteins: a comparison between healthy and obese females. J.Clin. Endocrinol. Metab. 2005, 90:1728-1733.
39. Aviram M., Rosenblat M., Billecke S., Erogul J., Sorenson R., Bisgaier C.L., et al. Human serum paraoxonase (PON1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radic. Biol. Med. 1999, 26:892-904.
40. Tanimoto N., Kumon Y., Suehiro T., Ohkubo S., Ikeda Y., Nishiya K., et al. Serum paraoxonase activity decreases in rheumatoid arthritis. Life Sci. 2003, 72:2877-2885.
41. Aviram M., Rosenblat M. Paraoxonases 1, 2, and 3, oxidative stress, and macrophage foam cell formation during atherosclerosis development. Free Radic. Biol. Med. 2004, 37:1304-1316.
42. Ferre N., Marsillach J., Camps J., Mackness B., Mackness M., Riu F., et al. Paraoxonase-1 is associated with oxidative stress, fibrosis and FAS expression in chronic liver diseases. J.Hepatol. 2006, 45:51-59.
43. Krzystek-Korpacka M., Patryn E., Hotowy K., Czapinska E., Majda J., Kustrzeba-Wojcicka I., et al. Paraoxonase (PON)-1 activity in overweight and obese children and adolescents: association with obesity-related inflammation and oxidative stress. Adv. Clin. Exp. Med. 2013, 22:229-236.
44. Liu L., Yu R., Shi Y., Dai Y., Zeng Z., Guo X., et al. Transduced protein transduction domain linked HSP27 protected LECs against UVB radiation-induced damage. Exp. Eye Res. 2014, 120:36-42.
45. Zhang X., Li Y., Cheng Y., Tan H., Li Z., Qu Y., et al. Tat-PTD-endostatin: a novel anti-angiogenesis protein with ocular barrier permeability via eye-drops. Biochim. Biophys. Acta 2015, 1850:1140-1149.
46. Jia X., Tian H., Tang L., Zheng L., Zheng L., Yang T., et al. High-efficiency expression of TAT-bFGF fusion protein in Escherichia coli and effect on hypertrophic scar tissue. PLOS One 2015, 10:e0117448.
47. Zhu Y., Bu Q., Liu X., Hu W., Wang Y. Neuroprotective effect of TAT-14-3-3ε fusion protein against cerebral ischemia/reperfusion injury in rats. PLOS One 2014, 9:e93334.
48. Teismann P., Schulz J.B. Cellular pathology of Parkinson's disease: astrocytes, microglia and inflammation. Cell Tissue Res. 2004, 318:149-161.
49. Lee E., Park H.R., Ji S.T., Lee Y., Lee J. Baicalein attenuates astroglial activation in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease model by downregulating the activations of nuclear factor-kB, ERK, and JNK. J.Neurosci. Res. 2014, 92:130-139.
50. Annese V., Herrero M.T., Di Pentima M., Gomez A., Lombardi L., Ros C.M., et al. Metalloproteinase-9 contributes to inflammatory glia activation and nigro-striatal pathway degeneration in both mouse and monkey models of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinsonism. Brain Struct. Funct. 2015, 220:703-727.